DRUG DEVELOPMENT Drug development involves long lead times, is very expensive and involves many variables of uncertainty. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to the Company. Every patient treated on future studies can change those assumptions either positively (to indicate a faster timeline to new drug applications and other approvals) or negatively (to indicate a slower timeline to new drug applications ...

Cybin Inc. Management's Discussion and Analysis of Financial Condition and Operating Performance For the three months ended June 30, 2023 Date: August 11, 2023 CYBIN INC. Management's Discussion and Analysis This Management's Discussion and Analysis ("MD&A") has been prepared by management of Cybin Inc. ("Cybin" or the "Company") and should be read in conjunction with Cybin's interim condensed consolidated financial statements and notes for the three months ended June 30, 2023 (the "Interim Financial Statem ...

Cybin Inc. Management's Discussion and Analysis of Financial Condition and Operating Performance For the three and nine months ended December 31, 2022 Date: February 13, 2023 CYBIN INC. Management's Discussion and Analysis This Management's Discussion and Analysis ("MD&A") has been prepared by management of Cybin Inc. ("Cybin" or the "Company") and should be read in conjunction with Cybin's interim condensed consolidated financial statements and notes for the three and nine months ended December 31, 2022 (t ...

Cybin Inc. Management's Discussion and Analysis of Financial Condition and Operating Performance For the three and six months ended September 30, 2022 Date: November 14, 2022 CYBIN INC. Management's Discussion and Analysis This Management's Discussion and Analysis ("MD&A") has been prepared by management of Cybin Inc. ("Cybin" or the "Company") and should be read in conjunction with Cybin's interim condensed consolidated financial statements and notes for the three and six months ended September 30, 2022 (t ...

Cybin Inc. (formerly Clarmin Explorations Inc.) Management's Discussion and Analysis of Financial Condition and Operating Performance For the three months ended June 30, 2022 Date: August 7, 2022 CYBIN INC. Management's Discussion and Analysis This Management's Discussion and Analysis ("MD&A") has been prepared by management of Cybin Inc. ("Cybin" or the "Company") and should be read in conjunction with Cybin's interim condensed consolidated financial statements and notes for the three months ended June 30, ...

® Cybin Announces Initiation of Kernel Flow Feasibility Study Measuring Psychedelic Effects on the Brain TORONTO, CANADA – March 31, 2022 – Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics ", today announced that the first study visit has been conducted in a Cybin-sponsored feasibility study evaluating Kernel's quantitative neuroimaging technology, Flow, to measure ketamine's psychedelic effects on cerebral co ...

Cybin , Inc. (NYSE:CYBN) Q3 2022 Earnings Conference Call February 10, 2022 8:30 AM ET Company Participants Leah Gibson - VP, IR Douglas Drysdale - CEO Conference Call Participants Sumant Kulkarni - Canaccord Genuity Charles Duncan - Cantor Fitzgerald & Co. Sepehr Manochehry - Eight Capital Jason Shieh - H.C. Wainright François Brisebois - Oppenheimer Andrew Partheniou - Stifel Nicolaus Michael Okunewitch - Maxim Group Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to ...

Cybin, Inc. (NYSE:CYBN) Q2 2022 Earnings Conference Call November 15, 2021 4:30 PM ET Company Participants Leah Gibson - VP of IR Doug Drysdale - CEO Aaron Bartlone - COO Mike Palfreyman - Chief R&D Officer Greg Cavers - CFO Eric So - Co-Founder, Executive Chairman and President Conference Call Participants Charles Duncan - Cantor Fitzgerald Sumant Kulkarni - Canaccord Patrick Trucchio - H.C. Wainwright Francois Brisebois - Oppenheimer Andrew Partheniou - Stifel Elemer Piros - ROTH Capital Partners Operator ...

Exhibit 99.2 Cybin Inc. (formerly Clarmin Explorations Inc.) Management's Discussion and Analysis of Financial Condition and Operating Performance For the three months ended June 30, 2021 Date: August 13, 2021 CYBIN INC. Management's Discussion and Analysis This Management's Discussion and Analysis ("MD&A") has been prepared by management of Cybin Inc. ("Cybin" or the "Company") and should be read in conjunction with Cybin's interim condensed consolidated financial statements and notes for the three months ...